Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

This Phase II trial (called RANGER) investigates personalised radiation therapy for men with prostate cancer that has risen again after prostatectomy (surgical removal of the prostate). It uses PSA blood test levels to guide how much hormone therapy is given alongside salvage radiotherapy, and whether radiation covers nearby lymph nodes. **You may be eligible if...** - You are a man aged 18 or older - You had surgery to remove your prostate (prostatectomy) for localised prostate cancer within the past 10 years - Your PSA level is rising or persistently elevated at 0.05 ng/mL or higher after surgery - There is no confirmed evidence that the cancer has spread to lymph nodes or distant sites - Your general health is good (ECOG 0–2) **You may NOT be eligible if...** - Your cancer has confirmed spread to lymph nodes or other organs - Less than 4 months have passed since your prostatectomy - Your overall health prevents radiotherapy Talk to your doctor to see if this trial is right for you.